SPOTLIGHT: Abbott teams with Genentech
Abbott Laboratories and Genentech have announced a new collaboration to develop and sell two cancer therapies. The two Abbott drugs-ABT-263 and ABT-869-have been in Phase I trials. No financial terms were disclosed in the announcement. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
